Intertek announced an expansion of the pharmaceutical services for specialist inhalation and nasal product development for biologics in Melbourne, near Cambridge.
The expansion of the new facility in 20,000 square feet will double the existing facility.
The new facility will provide over 100 additional employment over the next four years.
The new facility will have additional space for inhalation and nasal drug testing, and also including laboratory space specifically for inhaled biologics formulation development.
New inhaled biologics present various classes of large molecules to treat the respiratory diseases, potentially targeted drug delivery to the lung, opening the new treatment pathways for diseases such as cystic fibrosis, asthma and lung cancer.
The construction of the facility is expected to be completed by the end of 2019.
|Melbourne, near Cambridge, U.K.
|Scheduled to be completed by the end of 2019